Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cue · stock forecast · 9 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$7.00
Consensus
$4.33
-85.1% upside
Low
$2.00
Median: $4 · Last Close: $29.08
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$4.33
-85.1% upside
High Target
$7
-75.9%
Low Target
$2
-93.1%
Current Price
$29.08
as of today
Based on analyst price targets, the CUE stock price prediction for the next 12 months ranges from $2 to $7. The consensus CUE price forecast of $4.33 implies -85.1% upside from the current price of $29.08.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $30.53 | ↑ 5.00% |
1-day model range: $30.08–$30.99. Peak: $30.99 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CUE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Citizens Capital Markets | Maintains | Market Outperform→Market Outperform |
| 2024-08-20 | Stifel | Maintains | Buy→Buy |
| 2024-07-26 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2024-07-26 | Piper Sandler | Maintains | Overweight→Overweight |
| 2024-04-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2024-04-09 | Stifel | Maintains | Buy→Buy |
| 2024-04-03 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-11-06 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-06-15 | Stifel | Maintains | Buy→Buy |
| 2023-05-15 | JMP Securities | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Cue Biopharma, Inc. (CUE) stock. Of the recent 26 rating actions, 0 were upgrades and 0 were downgrades. 9 analysts currently cover CUE.
Analyst Recommendation Trends
CUE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$7M
↑ 550.0% YoY
Revenue Next Year
$13M
↑ 96.9% YoY
EPS This Year
$-12.00
EPS Next Year
$-6.64
↓ 44.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast CUE EPS of $-12.00 for the current fiscal year, based on estimates from 1 analysts. The CUE revenue forecast is $7M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CUE stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CUE price target is $4.33 (-85.1% upside), with an analyst consensus of Buy.
The CUE short-term stock prediction for tomorrow is $30.53 (+5.00%).
Cue Biopharma, Inc. trades on NASDAQ under the ticker CUE. The CUE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CUE forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month CUE price target is $4.33, with a high forecast of $7.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies -85.1% potential upside from the current price of $29.08.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.